A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Recruiting now · Phase 2/Phase 3

Conditions studied: Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration

In brief

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.

Key facts

Study ID
NCT07440225
Run by
EyeBiotech Ltd.
People needed
960
Starts
2026-03-27
Expected to finish
2028-06-30
Last updated by the study team
2026-08-06

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.